News

Caretaker Medical Awarded the Grand Prize in NIH RADx Tech for Maternal Health Challenge

Caretaker Medical, a digital health company focused on developing hemodynamic monitoring devices, today announced that it has been awarded the $525,000 grand prize in the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Technology for Maternal Health Challenge. The award recognizes Caretaker’s wireless, wearable wrist device, VitalStream, that can be used to monitor postpartum women for episodes of hyper- or hypotension, as well as detect the early onset of hemorrhage and sepsis. VitalStream continuously measures heart rate, blood pressure, respiration, cardiac output and stroke volume, among other vital signs.

In the US, over 80% of pregnancy-related deaths are preventable. And in 2020, 36% of deaths occurred 1-42 days postpartum. Continuous monitoring can help clinicians detect clinical decompensation sooner. A noninvasive, wireless monitor can expand advanced monitoring capabilities to more women and can potentially even be worn after hospital discharge.

“We are honored to receive this award and to be recognized for VitalStream’s potential to impact maternal health outcomes,” stated Jeff Pompeo, President and CEO of Caretaker Medical. “VitalStream can offer clinicians the continuous data they need to intervene earlier, potentially save the lives of new mothers.”

The RADx challenge prioritized technologies that are innovative, easy to use and can be used to help reduce health disparities.

For more information or to schedule a demonstration, contact Caretaker Medical.

Read more here.

Recent News

03/24/2026

Prolight reports positive Traumatic Brain Injury (TBI) biomarker results with BRAINBox Solutions, confirming broad assay potential of the Psyros™ POC platform

Prolight Diagnostics, a leader in point-of-care (POC) technology, today announces positive results from a collaboration with BRAINBox Solutions, a leader in multi-modality diagnostic and prognostic tests for traumatic brain injury (TBI). The analytic evaluation shows strong performance across a unique combination of three traumatic brain injury biomarkers, demonstrating the ease with which multiple novel markers can be transferred onto the Psyros uniquesingle-molecule-counting platform and reinforcing its potential to improve

03/24/2026

ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO

ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointments of Howard Berman, Ph.D., as Chairman and Chief Executive Officer and Kia Motesharei, Ph.D., as President and Chief Operating Officer. Dr. Berman, who has

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing